{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:41:54Z","timestamp":1789753314879,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministero della Sanit\u00e0"},{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"publisher","award":["IG:18467"],"award-info":[{"award-number":["IG:18467"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jconrel.2018.03.016","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T18:56:59Z","timestamp":1521399419000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma"],"prefix":"10.1016","volume":"277","author":[{"given":"Emily","family":"Capone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-4509","authenticated-orcid":false,"given":"Alessia","family":"Lamolinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Laurenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-915X","authenticated-orcid":false,"given":"Gianluca","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.03.016_bb0005","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-017-0325-6","article-title":"Advanced melanoma: current treatment options, biomarkers, and future perspectives","author":"Rozeman","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0010","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/CCID.S120877","article-title":"Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis","volume":"10","author":"Karlsson","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PPO.0b013e31824b436e","article-title":"Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies","volume":"18","author":"Kudchadkar","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0035","first-page":"1","article-title":"Emerging anti-cancer antibodies and combination therapies targeting HER3\/ERBB3","author":"Gaborit","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.18632\/aging.100850","article-title":"HER-3: hub for escape mechanisms","volume":"7","author":"Capone","year":"2015","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1476-4598-13-105","article-title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment","volume":"13","author":"Ma","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0050","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0055","first-page":"479","volume":"3","author":"Enhanced ERBB3 Signaling Promotes Resistance in Melanoma","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0060","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.1018001108","article-title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors","volume":"109","author":"Chakrabarty","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0065","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-13-1549","article-title":"Molecular pathways: HER3 targeted therapy","volume":"20","author":"Gala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0070","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/jcp.24037","article-title":"Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors","volume":"227","author":"Aurisicchio","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/21645515.2015.1102809","article-title":"Emerging anti-cancer antibodies and combination therapies targeting HER3\/ERBB3","volume":"12","author":"Gaborit","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0085","article-title":"Antibody-drug conjugates: design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France","volume":"0","author":"Martin","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0095","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0100","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1093\/annonc\/mdx541","article-title":"The antibody-drug conjugate target landscape across a broad range of tumour types","volume":"28","author":"Moek","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0105","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/onc.2011.322","article-title":"An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3\/Akt signaling","volume":"31","author":"Sala","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1593\/tlo.13475","article-title":"C.I.N.P.L.B.-O. (CINBO), EV20, a novel anti-ErbB-3 humanized antibody, promotes ErbB-3 down-regulation and inhibits tumor growth in vivo","volume":"6","author":"Sala","year":"2013","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0120","doi-asserted-by":"crossref","first-page":"95412","DOI":"10.18632\/oncotarget.20728","article-title":"EV20-sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma","volume":"8","author":"Capone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0125","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","article-title":"DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice","volume":"165","author":"Rovero","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0130","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1038\/sj.onc.1206516","article-title":"Feedback inhibition by RALT controls signal output by the ErbB network","volume":"22","author":"Anastasi","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0140","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody-drug conjugate-based therapeutic approaches","volume":"40","author":"de Goeij","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0150","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.18632\/oncotarget.4642","article-title":"ErbB-3 activation by NRG-1beta sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)","volume":"6","author":"Prasetyanti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0160","article-title":"Dual targeting of ErbB-2\/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer","volume":"3","author":"Ghasemi","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.03.016_bb0165","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0175","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.03.016_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918301378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918301378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T01:34:54Z","timestamp":1534988094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918301378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":36,"alternative-id":["S0168365918301378"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}